<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141185">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01844583</url>
  </required_header>
  <id_info>
    <org_study_id>C14015</org_study_id>
    <nct_id>NCT01844583</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib</brief_title>
  <official_title>Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, tolerability and PK of concomitant esomeprazole and rifampin, and QT study on single
      and multiple-doses of alisertib
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>alisertib PK parameters (AUC and Cmax) in the presence (Cycle 2 Day 8) versus absence (Cycle 1 Day 1) of esomeprazole</measure>
    <time_frame>Cycle 2, Day 8 and Cycle 1, Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimation of effect of esomeprazole on alisertib pharmacokinetics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alisertib PK parameters (AUC and Cmax) in the presence (Cycle 2 Day 8) versus absence (Cycle 1 Day 1) of rifampin</measure>
    <time_frame>Cycle 2, Day 8 and Cycle 1, Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimation of effect of rifampin on alisertib pharmacokinetics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QTc following single and multiple dose administration of alisertib</measure>
    <time_frame>Cycle 1 Days -1, 1, 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimation of effect of alisertib on the ECG QTc interval by 12-lead Holter monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>alisertib steady-state PK parameters (AUC and Cmax)</measure>
    <time_frame>Cycle 1, Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of steady-state alisertib pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>From signing of the informed consent form through 30 days after the last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events (AEs), serious adverse events (SAEs), assessments of clinical and laboratory values, and vital sign measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG intervals following single and multiple dose administration of alisertib</measure>
    <time_frame>Cycle 1, Days -1, 1, 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimation of effect of alisertib on ECG intervals by 12-lead Holter monitoring</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>alisertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Timeframe: 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alisertib</intervention_name>
    <arm_group_label>alisertib</arm_group_label>
    <other_name>MLN8237</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
    <arm_group_label>alisertib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampin</intervention_name>
    <arm_group_label>alisertib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years or older

          -  Histologically or cytologically confirmed metastatic and/or advanced solid tumors or
             lymphomas

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Expected survival longer than 3 months from enrollment in the study

          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2
             effective methods of contraception or agree to abstain from heterosexual intercourse

          -  Male patients who agree to practice effective barrier contraception or agree to
             abstain from heterosexual intercourse

        Exclusion Criteria:

          -  Treatment with any anticancer therapy or any investigational agents within 4 weeks
             before the first dose of alisertib

             -      Known hypersensitivity or intolerance to rifampin (for patients considered for
             the rifampin DDI group) or to esomeprazole (for patients considered for the
             esomeprazole DDI group)

          -  Recurrent nausea and/or vomiting within 14 days before the first dose of alisertib,
             and known GI abnormality or GI procedure that could interfere with or modify the oral
             absorption or tolerance of alisertib

          -  Patients requiring treatment with clinically significant enzyme inducers within 14
             days before the first dose of alisertib and/or requiring the use of these medications
             during the study

          -  A medical condition requiring use of pancreatic enzymes; or daily, chronic, or
             regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists

          -  Patients requiring systemic anticoagulation (excluding low-dose aspirin, or low-dose
             anticoagulation to maintain patency of venous access devices).

          -  Any cardiovascular condition

          -  Female patients who are lactating or have a positive serum pregnancy test

          -  Major surgery within the 14 days preceding the first dose of alisertib

             -      Life-threatening or uncontrolled medical illness unrelated to cancer

          -  Newly diagnosed or uncontrolled cancer-related central nervous system (CNS) disease

          -  Autologous stem cell transplant within 3 months

          -  Prior allogeneic bone marrow or other organ transplantation

             -      Other severe acute or chronic medical or psychiatric condition

          -  Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface
             antigen-positive status, or known or suspected active hepatitis C infection

        Please note there are additional inclusion and exclusion criteria.  The study center will
        determine if you meet all of the criteria.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Millennium Medical and Drug Information Center</last_name>
    <phone>1-877-674-3784</phone>
    <email>medical@mlnm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Patel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Lockhart</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shubham Pant</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Bauer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Nemunaitis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Drug Devt Cancer Therapy &amp; Research Ctr</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3271</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sarantopoulos</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
